North Bay Business Journal

BioMarin acquires LEAD Therapeutics

February 5th, 2010

NOVATO — BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said it plans to acquire LEAD Therapeutics Inc. of San Bruno in a stock deal worth $18 million up front and up to $97 million as the drug is submitted for government review and later released.

Lists Online
Click for a digital replica of the printed edition
Nominations close Feb. 10, 2012
Registration ends Feb. 17, 2012
Registration ends March 9, 2012
NBBJ Insider blog
- Occupy Santa Rosa vs. Exchange Bank: The wrong target December 9, 2011
Top News
Most popular recent items
- Bulk-wine inventory hits 12-year low 7941 view(s) | posted on January 19, 2012
- Forecast: Wine, grape prices to rise in 2012 3283 view(s) | posted on January 25, 2012
- Horizon to add San Diego flights; Vegas out 2319 view(s) | posted on January 18, 2012
Latest reader comments
- Jeff Quackenbush, Business Journal Staff Reporter on Letter to the Editor: Save a park, run for Annadel
- Penny Bellus on Napa Farmers Market to open near Oxbow May 1
Lary Kirchenbauer columns
- Leadership Obstacles: There’s no one to blame … except yourself | Special Bonus Today January 31, 2012
Previous articles
Business Journal connections